# Noveltreat Prescribing Guide

> Bedside prescribing reference for Noveltreat (Sun Pharma semaglutide 0.25/0.5/1/1.7/2.4 mg pre-filled pen) for chronic weight management — adult indication criteria, 5-step dose escalation, missed-dose rule, contraindications, warnings, drug interactions, and red-flag stop signals. Use when a clinician asks how to start Noveltreat, how to titrate semaglutide 2.4 mg, Noveltreat missed dose, Noveltreat contraindications, Noveltreat drug interactions, or when a patient on Noveltreat needs a monograph-level clinical decision. Grounded in Sun Pharmaceutical Industries Ltd. Product Monograph — Diabetes and Obesity (2026).

- Skill: `dromlakhani/noveltreat-prescribing-guide` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/noveltreat-prescribing-guide`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/noveltreat-prescribing-guide/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/noveltreat-prescribing-guide

---


# Noveltreat (Semaglutide 0.25 / 0.5 / 1 / 1.7 / 2.4 mg) — Prescribing Guide

## Indication (adults)

Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

- **BMI ≥ 30 kg/m²** (obesity), **OR**
- **BMI ≥ 27 kg/m²** (overweight) **with ≥ 1 weight-related comorbidity** — hypertension, type 2 diabetes, or dyslipidemia.

Maintenance dose: **2.4 mg once weekly** (SC).

## Contraindications

- Hypersensitivity to semaglutide or excipients
- **Pregnancy**
- Personal or family history of **medullary thyroid carcinoma (MTC)** or **multiple endocrine neoplasia type 2 (MEN 2)**
- History of **pancreatitis**

## Dose Escalation (once-weekly SC, every 4 weeks)

| Week | Weekly dose |
|---|---|
| 1–4 | 0.25 mg |
| 5–8 | 0.5 mg |
| 9–12 | 1.0 mg |
| 13–16 | 1.7 mg |
| 17 + | **2.4 mg (maintenance)** |

- Escalate every 4 weeks to improve GI tolerance.
- Continue the **highest tolerated effective dose**; adjust background insulin or sulfonylurea if co-prescribed.

## Missed Dose

- Take **within 5 days** of the scheduled day → administer, then resume the regular weekly schedule.
- **> 5 days late** → skip; resume on the next scheduled day.
- **Changing injection day:** ensure **≥ 48 h** between the last dose and the new day.

## Administration

- Subcutaneous injection — abdomen, thigh, or upper arm. Rotate sites.
- Same day each week; any time of day, with or without food.
- Single-use pre-filled pen — needle is hidden and pen auto-locks after use.

## Special Populations

| Population | Adjustment |
|---|---|
| Hepatic impairment | No dose adjustment |
| Renal impairment (mild–severe) | No dose adjustment; caution on initiation and escalation |
| Dialysis (HD or PD) | No dose adjustment recommended; evidence limited — use caution |
| Pregnancy / breastfeeding | **Contraindicated** |

## Warnings and Precautions

1. **Pancreatitis** — immediate cessation if suspected. **Do not resume** if confirmed.
2. **Diabetic retinopathy** — monitor closely in patients with a prior history.
3. **Hypoglycemia risk** with insulin or sulfonylurea → lower the dose of the secretagogue or insulin before or at initiation.
4. **Renal function** — monitor in renal impairment if severe GI reactions (vomiting, diarrhoea, dehydration) occur.
5. **Hypersensitivity** — discontinue if suspected; seek medical advice promptly.

## Drug Interactions

| Interaction | Effect | Action |
|---|---|---|
| ↓ Gastric emptying | Delayed absorption of oral drugs | Monitor narrow-therapeutic-index drugs |
| + Insulin / sulfonylurea | ↑ hypoglycemia risk | Reduce insulin or SU dose |
| Other GLP-1 RA / tirzepatide | Redundant mechanism | **Avoid combination** (contraindicated) |
| β-blockers, MAOIs, SSRIs, quinolones, salicylates, antidiabetics | ↑ hypoglycemic effect | Monitor glucose |
| Furosemide, thiazides, ritodrine | ↓ glycemic efficacy | Monitor glucose |
| Levothyroxine | ↑ serum levels | Monitor thyroid function |

## Adverse Effects

- **GI (most common):** nausea, vomiting, diarrhoea, constipation, abdominal pain.
- Dizziness, mild tachycardia, headaches, dyspepsia, infections.
- Injection-site reactions; rare anaphylaxis.
- Low intrinsic risk of hypoglycemia and acute kidney injury.

## Red Flags — When to Stop Noveltreat

- Persistent severe GI intolerance
- Symptoms suggesting pancreatitis (abdominal pain with nausea/vomiting)
- Vision changes (possible retinopathy)
- Thyroid nodule or dysphonia — evaluate for MTC
- **Serum calcitonin > 50 ng/L** — evaluate further for MTC; evaluate thyroid nodules on exam or neck imaging

## Overdose

- **Signs:** severe nausea, vomiting, hypoglycemia.
- **No specific antidote.** Supportive care based on clinical presentation.
- **Prolonged observation** may be needed — half-life ~1 week; drug remains in circulation ~5 weeks after the last dose.

## Cross-References

- Storage and pen handling → `noveltreat-storage-handling`
- Matching a patient to trial evidence → `noveltreat-patient-profile-matcher`
- Insulin / SU dose reduction on initiation → `glp1-insulin-su-dose-reduction`
- GI adverse-event management → `glp1-gi-ae-symptom-advisor`, `glp1-gi-ae-pharmacological-rescue`, `glp1-dose-escalation-troubleshooter`
- Pancreatobiliary monitoring → `glp1-pancreatobiliary-risk-monitor`
- Pre-procedure / perioperative → `glp1-perioperative-aspiration`, `glp1-endoscopy-pre-procedure`

## Reference

Sun Pharmaceutical Industries Ltd. **Product Monograph — Diabetes and Obesity (Sematrinity® and Noveltreat®)**, 2026 (Data on file).